KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Elanco Animal Health (ELAN) EBITDA (2017 - 2025)

Elanco Animal Health's EBITDA history spans 9 years, with the latest figure at $158.0 million for Q4 2025.

  • For Q4 2025, EBITDA rose 128.62% year-over-year to $158.0 million; the TTM value through Dec 2025 reached $795.0 million, up 152.48%, while the annual FY2025 figure was $795.0 million, 152.48% up from the prior year.
  • EBITDA for Q4 2025 was $158.0 million at Elanco Animal Health, down from $167.0 million in the prior quarter.
  • Across five years, EBITDA topped out at $249.0 million in Q1 2025 and bottomed at -$1.6 billion in Q3 2023.
  • The 5-year median for EBITDA is -$514.5 million (2022), against an average of -$426.6 million.
  • The largest annual shift saw EBITDA tumbled 206.98% in 2023 before it soared 149.5% in 2025.
  • A 5-year view of EBITDA shows it stood at -$635.0 million in 2021, then rose by 15.59% to -$536.0 million in 2022, then fell by 19.96% to -$643.0 million in 2023, then rose by 14.15% to -$552.0 million in 2024, then surged by 128.62% to $158.0 million in 2025.
  • Per Business Quant, the three most recent readings for ELAN's EBITDA are $158.0 million (Q4 2025), $167.0 million (Q3 2025), and $221.0 million (Q2 2025).